Floatz logo

280 assets in Pancreatic Ductal Adenocarcinoma

Therapeutic assets addressing Pancreatic Ductal Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Precemtabart Tocentecan
Pancreatic Ductal Adenocarcinoma
EMD Serono Research & Development Institute, Inc.P1/2CC (43)
Pyrvinium
Pancreatic Ductal Adenocarcinoma
Thomas Jefferson UniversityP1CC (43)
TIL
Pancreatic Ductal Adenocarcinoma
City of Hope Medical CenterP1CC (43)
Zimberelimab
Pancreatic Ductal Adenocarcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
68ga-ff58
Pancreatic Ductal Adenocarcinoma
Novartis PharmaceuticalsP1CC (42)
Promitil
Pancreatic Ductal Adenocarcinoma
Lipomedix Pharmaceuticals Inc.P2CC (42)
[18F]FPyQCP
Pancreatic Ductal Adenocarcinoma
Blue Earth DiagnosticsP1/2CC (41)
[203pb]pb-psv359
Pancreatic Ductal Adenocarcinoma
Perspective TherapeuticsP1/2CC (41)
[212pb]pb-psv359
Pancreatic Ductal Adenocarcinoma
Perspective TherapeuticsP1/2CC (41)
Afnt-211
Pancreatic Ductal Adenocarcinoma
Affini-T Therapeutics, Inc.P1/2CC (41)
Alnodesertib
Pancreatic Ductal Adenocarcinoma
Artios Pharma LtdP1/2CC (41)
Alta3263
Pancreatic Ductal Adenocarcinoma
Alterome Therapeutics, Inc.P1CC (41)
Arsenic Trioxide
Pancreatic Ductal Adenocarcinoma
Daniel BreadnerP1CC (41)
Autologous Mesothelin-Specific Tcr-T Cells
Pancreatic Ductal Adenocarcinoma
Fred Hutchinson Cancer CenterP1CC (41)
ava6103
Pancreatic Ductal Adenocarcinoma
Avacta Life Sciences LtdP1CC (41)
azd4360
Pancreatic Ductal Adenocarcinoma
AstraZenecaP1/2CC (41)
azd5863
Pancreatic Ductal Adenocarcinoma
AstraZenecaP1/2CC (41)
Bbo-10203
Pancreatic Ductal Adenocarcinoma
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)P1CC (41)
Bbo-11818
Pancreatic Ductal Adenocarcinoma
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)P1CC (41)
Bendamustine
Pancreatic Ductal Adenocarcinoma
Fred Hutchinson Cancer CenterP1CC (41)
Bgb-53038
Pancreatic Ductal Adenocarcinoma
BeOne MedicinesP1CC (41)
Bl-M05D1
Pancreatic Ductal Adenocarcinoma
SystImmune Inc.P1CC (41)
Blu-924
Pancreatic Ductal Adenocarcinoma
Blueprint Medicines CorporationP1/2CC (41)
ct3001
Pancreatic Ductal Adenocarcinoma
Crossignal Therapeutics, Inc.P1/2CC (41)
ddx5 degrader fl118
Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer InstituteP1CC (41)
Docetaxel
Pancreatic Ductal Adenocarcinoma
Phanes TherapeuticsP1/2CC (41)
Emavusertib
Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)P1CC (41)
H-Gamma1 Heavy Chain Anti-Cd47 (1-444), G1V92-1 Vh E44, Ch1 E77 [Vh E44 (Homo Sapiens Ighv1-46*01 (87.6%) Q44>E (39') -(Ighd) -Ighj4*01 (100%), Cdr-Imgt [8.8.7] (26-33.51-58.97-103)) (1-114) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 E77, G1V93 Ch1 C12, G1V37 H S5, G1V74 Ch3 C10, G1V32 Ch3 W22 (Knob) (Ch1 K12>C (130), G77>E (163), K120 (211) (115-212), Hinge 1-15 C5>S (217) (213-227), Ch2 (228-337), Ch3 S10>C (351), D12 (353), L14 (355), T22>W (363) (338-442), Chs (443-444)) (115-444)], (130-209')- Disulfide With L-Kappa Light Chain Anti-Cd47 (1'-214') Kv92-1 V-Kappa K44, C-Kappa K3 [V-Kappa K44 (Homo Sapiens Igkv3-20*01 (83.3%) Q44>K (38') -Igkj1*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (98.1%) Km3 A45.1, V101, K3, Kcv37 C121, S126 (C-Kappa S3>K (114'), A45.1 (153'), V101 (191'), F121>C (209'), C126>S (214')) (108'-214')]; H-Gamma1 Heavy Chain Anti-Cldn18 (1-449), G1V92-2 Vh K44, Ch1 K77 [Vh K44 (Homo Sapiens Ighv3-48*01 (87.8%) Q44>K (39'') -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'') -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, Ch1 K77, G1V75 Ch3 C5, G1V33 Ch3 S22, A24, V86 (Hole) (Ch1 G77>K (168''), K120 (216'') (120''-217''), Hinge 1-15 (218''-232''), Ch2 (233''-342''), Ch3 Y5>C (351''), D12 (358''), L14 (360''), T22>S (368''), L24>A (370''), Y86>V (409'') (343''-447''), Chs (448''-449'')) (120''-449'')], (222''-220''')-Disulfide With L-Kappa Light Chain Anti-Cldn18 (1'''-220''') Kv92-2 V-Kappa E44, C-Kappa E3 [V-Kappa E44 (Musmus/Homsap (Mus Musculus Igkv8-19*01 (79.2%) Q44>E (44''') -Igkj2*03 (81.8%) S120>Q (106'''), L124>V (110''')/Homo Sapiens Igkv1-39*01 (78.2%) Q44>E (44''') -Igkj1*01 (100%), Cdr -Imgt [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo Sapiens Igkc*01 (99.1%) Km3 A45.1, V101, E3 (C-Kappa S3>E (120'''), A45.1 (159'''), V101 (197''')) (114'''-220''')]; Dimer (223-228'':226-231'':351-351'')-Trisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa
Pancreatic Ductal Adenocarcinoma
Phanes TherapeuticsP1/2CC (41)
Icovamenib
Pancreatic Ductal Adenocarcinoma
Biomea Fusion Inc.P1CC (41)
Imiquimod
Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer CenterP1CC (41)
ipn01194
Pancreatic Ductal Adenocarcinoma
IpsenP1/2CC (41)
Mavrostobart
Pancreatic Ductal Adenocarcinoma
Phanes TherapeuticsP1/2CC (41)
Mesenchymal Stem Cells Derived Exosomes
Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer CenterP1/2CC (41)
Midazolam
Pancreatic Ductal Adenocarcinoma
Alterome Therapeutics, Inc.P1CC (41)
Mutant Kras G12V-Specific Tcr Transduced Autologous T Cells
Pancreatic Ductal Adenocarcinoma
Changhai HospitalP1/2CC (41)
Nesuparib
Pancreatic Ductal Adenocarcinoma
Onconic Therapeutics Inc.P1/2CC (41)
ngm707
Pancreatic Ductal Adenocarcinoma
NGM Biopharmaceuticals, IncP1/2CC (41)
Nlm-001
Pancreatic Ductal Adenocarcinoma
Nelum CorpP1/2CC (41)
Tegavivint
Pancreatic Ductal Adenocarcinoma
Children's Oncology GroupP1/2CC (41)
tj033721
Pancreatic Ductal Adenocarcinoma
I-Mab Biopharma US LimitedP1CC (41)
Tretinoin
Pancreatic Ductal Adenocarcinoma
Daniel BreadnerP1CC (41)
Zalifrelimab
Pancreatic Ductal Adenocarcinoma
Nelum CorpP1/2CC (41)
Zunsemetinib
Pancreatic Ductal Adenocarcinoma
Washington University School of MedicineP1CC (41)
Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101)
Pancreatic Ductal Adenocarcinoma
Fudan UniversityP1CC (40)
ro7496353
Pancreatic Ductal Adenocarcinoma
Genentech, Inc.P1CC (40)
Ruxolitinib
Pancreatic Ductal Adenocarcinoma
Peter Hosein, MDP1CC (40)
Sotigalimab
Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer CenterP1CC (40)
Trametinib
Pancreatic Ductal Adenocarcinoma
Peter Hosein, MDP1CC (40)
[111in]-fpi-2058
Pancreatic Ductal Adenocarcinoma
3B Pharmaceuticals GmbHP1C (39)
[225]-fpi-2059
Pancreatic Ductal Adenocarcinoma
3B Pharmaceuticals GmbHP1C (39)
Showing 151 to 200 of 280 assets
PreviousPage 4 of 6Next